SAN ANTONIO, Oct. 24 – In improving its biomanufacturing capacity, Scorpius Holdings (SCPX, Financial) has teamed up with a U.S.-based biotechnology company. Under the deal, the biotech company will work with program management team of Scorpius in moving research cell bank to sophisticated facilities in San Antonio, Texas, where biomanufacturing operations will take place from there on.
The cooperation seeks to meet the growing demand for safe, U.S.-based development and manufacturing support for innovative biologics research. Jeff Wolf, the CEO of Scorpius, underlined the part the business plays in fostering biotech innovation. "This collaboration highlights how well Scorpius can assist biotech businesses at all phases of their development, from creative research to clinical trials," Wolf said.
With a focus on offering complete manufacturing solutions ranging from early-stage research to clinical-scale production, Scorpius Holdings keeps growing its presence in the biotech industry. By means of this cooperation, the company seeks to address the growing demand for safe and dependable production infrastructure, therefore strengthening its position as a major participant in the U.S. biomanufacturing scene.
